Skip to Content
Merck
CN

Key Documents

View All Documentation

453R-2

p53 (EP9) Rabbit Monoclonal Primary Antibody

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
EP9, monoclonal
Application:
IHC (p)
Citations:
9
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

rabbit

Quality Level

100, 500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP9, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (453R-24), vial of 0.1 mL concentrate Research Use Only (453R-24-RUO), vial of 0.5 mL concentrate (453R-25), bottle of 1.0 mL predilute ready-to-use (453R-27), vial of 1.0 mL concentrate (453R-26), vial of 1.0 mL concentrate Research Use Only (453R-26-RUO), vial of 1.0 mL pre-dilute Research Use Only (453R-27-RUO), bottle of 7.0 mL predilute ready-to-use (453R-28), vial of 7.0 mL pre-dilute ready-to-use Research Use Only (453R-28-RUO)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrate)

control

breast carcinoma ((breast ductal carcinoma in-situ)), colorectal carcinoma, ovarian carcinoma ((ovarian serous carcinoma)), urothelial carcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... TP53(7157)

General description

Anti-p53 tumor suppressor protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53, although significant accumulation of the mutant form of p53 protein due to longer half-life is the basis for the test using the IHC technique. Nuclear staining with this antibody has been shown in breast carcinoma, lung carcinoma, colorectal carcinoma, and urothelial carcinoma.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot

Analysis Note

United States - IVD
Canada - IVD
European Union - IVD
Japan - RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
p53 Positive Control Slides, Product No. 453S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Try our Product Selector Tool to narrow your options

Storage Class

12 - Non Combustible Liquids

wgk

WGK 2

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000249694
0000262585
0000264388
0000262585
0000249694

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Diagnostic Immunohistochemistry (Masson Publishing), Page 701-Page 702 (2006)
J K McKenney et al.
The American journal of surgical pathology, 25(8), 1074-1078 (2001-07-28)
Distinction of urothelial carcinoma in situ (CIS) from reactive atypia on the basis of morphology alone may be difficult in some cases. Because this distinction is therapeutically and prognostically critical, we attempted to determine if an immunohistochemical panel would help
David J Dabbs et al.
The American journal of surgical pathology, 37(7), e1-11 (2013-06-14)
Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are
View All Related Papers

Global Trade Item Number

SKUGTIN
453R-2404061837571701
453R-2604061837571749
453R-28-RUO04061837571794
453R-24-RUO04061837571718
453R-2704061837571763
453R-25-RUO04061837571732
453R-26-RUO04061837571756
453R-2504061837571725
453R-2804061837571787
453R-27-RUO04061837571770